TransCode Therapeutics, Inc.

As of October 5, 2023, TransCode Therapeutics, Inc. is considered attractive and undervalued, with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers like Moderna and BioNTech, and showing strong financial health.

As of October 1, 2023, there is insufficient technical data for TransCode Therapeutics, Inc. to determine a bullish or bearish outlook.

TransCode Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $12 million and a market cap of $5.69 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.12.

As of Jun 18, TransCode Therapeutics, Inc. has a market capitalization of 5.69 million and reported net sales of 0.00 million with a net profit of -25.52 million over the last four quarters. Shareholder's funds were -2.02 million, and total assets amounted to 7.29 million.